Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.
暂无分享,去创建一个
[1] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[2] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Antonescu,et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.
[5] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Blay,et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[8] Y. Novitsky,et al. Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors , 2006, Annals of surgery.
[9] J. Desai,et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[11] M. van Glabbeke,et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[13] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[14] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[15] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[16] G. Demetri,et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.